nach oben

Cancer and Metastasis Reviews

Erschienen in:

13.02.2023 | COMMENTARY

Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?

verfasst von: Charles N. Serhan, Megan L. Sulciner

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Uncontrolled inflammation giving rise to excessive tissue inflammation can lead to chronic inflammation that enhances tissue destruction, amplifying many chronic human pathologies. Normally the acute inflammatory response is protective and should be self-limited returning tissues to functional homeostasis with endogenous programmed resolution via leukocyte vasculature cell-cell interactions and crosstalk that biosynthesize pro-resolving mediators. When failed resolution takes place, as with the use of NSAIDs, tissues undergo chronic inflammation and fibrosis. Herein, we discuss these mechanisms and the role of specialized proresolving mediators, the resolvins, protectins and maresins produced from essential omega-3 fatty acids EPA and DHA, and their contributions via their cognate cell surface receptors, to the resolution response. Harnessing these pathways and their cellular mechanisms can help in providing new therapeutic approaches to many human diseases, infections, organ protection and trauma via resolution medicine to enhance the body’s own resilience to challenge.

Tufte, E. R. (2002). The visual display of quantitative information (Second.). Graphics Press.

Braunwald, E., Isselbacher, K., Petersdorp, R., Wilson, J., Martin, J., & Fauci, A. (Eds.). (1986). Harrison’s principles of internal medicine (11th ed.).

Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature, 510(7503), 92–101. https://doi.org/10.1038/nature13479CrossRefPubMedPubMedCentral

Fu, X., Yin, H.-H., Wu, M.-J., He, X., Jiang, Q., Zhang, L.-T., & Liu, J.-Y. (2022). High sensitivity and wide linearity LC-MS/MS method for oxylipin quantification in multiple biological samples. Journal of Lipid Research, 63(12), 100302. https://doi.org/10.1016/j.jlr.2022.100302CrossRefPubMedPubMedCentral

Colas, R. A., Shinohara, M., Dalli, J., Chiang, N., & Serhan, C. N. (2014). Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. American Journal of Physiology. Cell Physiology, 307(1), C39–C54. https://doi.org/10.1152/ajpcell.00024.2014CrossRefPubMedPubMedCentral

Noureddine, N., Hartling, I., Wawrzyniak, P., Srikanthan, P., Lou, P.-H., Lucchinetti, E., et al. (2022). Lipid emulsion rich in n-3 polyunsaturated fatty acids elicits a pro-resolution lipid mediator profile in mouse tissues and in human immune cells. The American Journal of Clinical Nutrition, 116(3), 786–797. https://doi.org/10.1093/ajcn/nqac131CrossRefPubMed

Schwab, J. M., Chiang, N., Arita, M., & Serhan, C. N. (2007). Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature, 447(7146), 869–874. https://doi.org/10.1038/nature05877CrossRefPubMedPubMedCentral

Perretti, M., & Dalli, J. (2022). Resolution pharmacology: focus on pro-resolving annexin A1 and lipid mediators for therapeutic innovation in inflammation. Annual Review of Pharmacology and Toxicology. https://doi.org/10.1146/annurev-pharmtox-051821-042743

Libby, P. (2021). Targeting inflammatory pathways in cardiovascular disease: the inflammasome, interleukin-1, interleukin-6 and beyond. Cells, 10(4). https://doi.org/10.3390/cells10040951

10.

Keeley, E. C., Li, H. J., Cogle, C. R., Handberg, E. M., Merz, C. N. B., & Pepine, C. J. (2022). Specialized proresolving mediators in symptomatic women with coronary microvascular dysfunction (from the women’s ischemia trial to reduce events in nonobstructive CAD [WARRIOR] trial). The American Journal of Cardiology, 162, 1–5. https://doi.org/10.1016/j.amjcard.2021.09.015CrossRefPubMed

11.

Barden, A. E., Shinde, S., Burke, V., Puddey, I. B., Beilin, L. J., Irish, A. B., et al. (2018). The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease. Prostaglandins & Other Lipid Mediators, 136, 1–8. https://doi.org/10.1016/j.prostaglandins.2018.03.002CrossRef

12.

Turnbull, J., Jha, R. R., Ortori, C. A., Lunt, E., Tighe, P. J., Irving, W. L., et al. (2022). Serum levels of proinflammatory lipid mediators and specialized proresolving molecules are increased in patients with severe acute respiratory syndrome coronavirus 2 and correlate with markers of the adaptive immune response. The Journal of Infectious Diseases, 225(12), 2142–2154. https://doi.org/10.1093/infdis/jiab632CrossRefPubMedPubMedCentral

13.

Schwarz, B., Sharma, L., Roberts, L., Peng, X., Bermejo, S., Leighton, I., et al. (2021). Cutting edge: severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome, resulting in dysregulation of eicosanoid immune mediators. Journal of Immunology, 206(2), 329–334. https://doi.org/10.4049/jimmunol.2001025CrossRef

14.

Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., et al. (2018). Resolvins suppress tumor growth and enhance cancer therapy. The Journal of Experimental Medicine, 215(1), 115–140. https://doi.org/10.1084/jem.20170681CrossRefPubMedPubMedCentral

15.

Kantarci, A., Kansal, S., Hasturk, H., Stephens, D., & Van Dyke, T. E. (2022). Resolvin E1 reduces tumor growth in a xenograft model of lung cancer. The American Journal of Pathology, 192(10), 1470–1484. https://doi.org/10.1016/j.ajpath.2022.07.004CrossRefPubMed

16.

Panigrahy, D., Gartung, A., Yang, J., Yang, H., Gilligan, M. M., Sulciner, M. L., et al. (2019). Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. The Journal of Clinical Investigation, 129(7), 2964–2979. https://doi.org/10.1172/JCI127282CrossRefPubMedPubMedCentral

17.

Uno, H., Furukawa, K., Suzuki, D., Shimizu, H., Ohtsuka, M., Kato, A., et al. (2016). Immunonutrition suppresses acute inflammatory responses through modulation of resolvin E1 in patients undergoing major hepatobiliary resection. Surgery, 160(1), 228–236. https://doi.org/10.1016/j.surg.2016.01.019CrossRefPubMed

18.

Zhang, L., Terrando, N., Xu, Z.-Z., Bang, S., Jordt, S.-E., Maixner, W., et al. (2018). Distinct analgesic actions of DHA and DHA-derived specialized pro-resolving mediators on post-operative pain after bone fracture in mice. Frontiers in Pharmacology, 9, 412. https://doi.org/10.3389/fphar.2018.00412CrossRefPubMedPubMedCentral

19.

Hasturk, H., Schulte, F., Martins, M., Sherzai, H., Floros, C., Cugini, M., et al. (2021). Safety and preliminary efficacy of a novel host-modulatory therapy for reducing gingival inflammation. Frontiers in Immunology, 12, 704163. https://doi.org/10.3389/fimmu.2021.704163CrossRefPubMedPubMedCentral

20.

Schädel, P., Troisi, F., Czapka, A., Gebert, N., Pace, S., Ori, A., & Werz, O. (2021). Aging drives organ-specific alterations of the inflammatory microenvironment guided by immunomodulatory mediators in mice. The FASEB Journal, 35(5), e21558. https://doi.org/10.1096/fj.202002684RCrossRefPubMed

21.

Sinha, G. (2022). Doubt cast on inflammation’s stop signals. Science, 376(6593), 565–566. https://doi.org/10.1126/science.abq8310CrossRefPubMed

22.

Trilleaud, C., Gauttier, V., Biteau, K., Girault, I., Belarif, L., Mary, C., et al. (2021). Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution. Science Advances, 7(14). https://doi.org/10.1126/sciadv.abd1453

23.

Roosevelt, T. (1910). Man in the arena. Citizenship in a Republic. Sorbonne.

24.

Leroy, V., Cai, J., Tu, Z., McQuiston, A., Sharma, S., Emtiazjoo, A., et al. (2022). Resolution of post-lung transplant ischemia-reperfusion injury is modulated via Resolvin D1-FPR2 and Maresin 1-LGR6 signaling. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2022.12.013

Titel: Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?
verfasst von: Charles N. Serhan
Megan L. Sulciner
Publikationsdatum: 13.02.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2023
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10091-5

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?

Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry

Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

Biography—Dr. David Gewirtz

Regulation of dormancy during tumor dissemination: the role of the ECM

Could senescence phenotypes strike the balance to promote tumor dormancy?

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie